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Abstract On the occasion of the 20th anniversary of the
Center for Alternative Methods to Animal Experiments
(ZEBET), an international symposium was held at the
German Federal Institute for Risk Assessment (BfR) in
Berlin. At the same time, this symposium was meant to
celebrate the 50th anniversary of the publication of the
book ‘‘The Principles of Humane Experimental Tech-
nique’’ by Russell and Burch in 1959 in which the 3Rs
principle (that is, Replacement, Reduction, and Reﬁnement)
has been coined and introduced to foster the development
of alternative methods to animal testing. Another topic
addressed by the symposium was the new vision on
‘‘Toxicology in the twenty-ﬁrst Century’’, as proposed by
the US-National Research Council, which aims at using
human cells and tissues for toxicity testing in vitro rather
than live animals. An overview of the achievements and
current tasks, as well as a vision of the future to be
addressed by ZEBET@BfR in the years to come is outlined
in the present paper.
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On the future of ZEBET
Some general considerations and thoughts
While ﬁnalizing the schedule and program of the 20th
anniversary symposium, ZEBET staff were highly inter-
ested in discussing the possible future direction of the
department in order to provide a proposal on how the future
of ZEBET might look like, as a milestone not too far away,
let us say—maybe in the forthcoming one or two decades.
Before going into what ZEBET’s future might look like,
it is worthwhile to assess the status quo and to praise what
has been achieved during the ﬁrst 20 years at this German
institution. Thus, the initial focus of this section will be the
current situation at ZEBET, how it is organized and
equipped, and what are its main tasks and commitments. In
addition, the current situation of animals used for scientiﬁc
purposes will be assessed, their numbers, and the trends in
alternatives to animal testing.
ZEBET is dedicated to all three facets of the 3Rs, that is,
replacement, reduction, and reﬁnement of testing in ani-
mals, which have been incorporated into the EU Directive
86/609 (Fig. 1). One of the main tasks of ZEBET is to
collect all available information on alternative methods to
animal testing and to provide an up-to-date science-based
assessment to its stakeholders. ZEBET is also pursuing in-
house research and develops modiﬁed or new bioassays
that would be suitable to replace animal experiments or to
reduce animal numbers subjected to particular in vivo
assays. At the same time, ZEBET is pushing for validation
of alternative methods developed through our own efforts
or by any other research group or consortium dedicated to
establish alternative methods. Ultimately, ZEBET is
interested in the safety evaluation of chemicals or biolog-
ical products based on alternative methods or testing
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but crude conventional toxicity testing in live animals.
To fulﬁll all of these tasks, ZEBET is organized in three
basic albeit overlapping units dedicated to documentation,
evaluation, and research (Fig. 2). Starting at the end of the
1980s as part of the now defunct German Federal Health
Authority (BGA), ZEBET is now part of the Federal
Institute for Risk Assessment (BfR) for more than 7 years.
Being subdivided into a set of different departments, the
portfolio of the BfR encompasses the areas of biological
safety, food safety, chemicals, and product safety, as well
as risk communication. All of these departments have
proved important and instrumental in supporting the work
and goals of ZEBET ever since the BfR has been estab-
lished in 2002. Incorporating ZEBET into the larger
institution of the BfR holds great promise and offers a
range of advantages mainly resulting from the interde-
partmental and interdisciplinary interactions. This has
occasionally resulted in unexpected progress and success
with some of those innumerable activities and engagements
initiated by ZEBET. Still, there is further and as yet
untapped potential of this structure awaiting to be fully
utilized and gainfully applied for the sake of both human
health and animal welfare.
Current status of animal experimentation in Europe
A total of about 12.1 million animals have been used in the
25 member states of the EU, according to a report of the
European Commission from November 2007, which pro-
vides an overview on the numbers of animals used for
scientiﬁc purposes in Europe in the year 2005 (Fig. 3)
(Commission of the European Communities 2007).
For comparison, a USDA/APHIS census estimated that
a total of 17–22 million animals were used in research and
testing in the US in 1983 (US Congress, Ofﬁce of
Technology Assessment 1986). However, a more recent
independent estimate suggests up to 80 million animals
used, in part due to the advent of transgenic animals
(Carbone 2004). The USDA publishes annual reports on
animal usage in research; however, those numbers exclude
birds, mice of the genus Mus, and rats of the genus Rattus
bred for use in research, according to animal welfare act
(AWA) regulations, and are therefore not included in the
1,131,076 animals reported in 2009 (US Department of
Agriculture, Animal and Plant Health Inspection Service
2009).
In Europe, of the animals used 79% are mammals, with
rodentia, and here mainly mice and rats, making up for
75% of total animals; another 2.6% are rabbits (Fig. 3).
The main areas of use are in basic science (33%) and
research and development (31%), followed by production
and quality control for medical products, substances, or
devices (15%).
For toxicology and safety evaluation, about 970,000
animals (8% of total) were used in 2005 (Fig. 4). Testing
for medical products, substances, or devices made the
largest part in this category with 51%, whereas animal use
for the evaluation of products or substances used mainly as
animal feed, foods, cosmetics, and household items amount
for only 4.3%. Chemicals and pesticides account for 19%
of toxicological and safety testing in animals. Fig. 1 ZEBET@BfR and the 3R principle
Fig. 2 Organization of ZEBET@BfR
Fig. 3 Animals used for scientiﬁc purposes in Europe. The chart
shows percentages of animals used by classes and have been taken
from the ﬁfth report on the statistics on the number of animals used
for experimental and other scientiﬁc purposes in the member states of
the European Union (Commission of the European Communities
2007)
842 Arch Toxicol (2011) 85:841–858
123From a science perspective, research related to animal
and human diseases is responsible for the largest share of
57% of total animals used (this includes the aforemen-
tioned research and development and the production and
quality control for medical products, substances, or devi-
ces), the second is fundamental biology studies (33%)
followed by toxicology and safety studies (8%) (Fig. 4).
The share of animals used for toxicology and safety eval-
uation dropped from 9.9% in 2002, when 15 EU countries
reported on their animal use, to 8% in 2005, when 25 EU
countries reported on their animal use. Despite the increase
in reporting countries, this amounts to nearly 40,000 ani-
mals less used. However, the total number of animals used
increased by 3.1% in the 15 EU countries reporting in both
2002 and 2005 (Fig. 5) (Commission of the European
Communities 2007). Similarly, there is a steady increase of
animal usage in Germany in the last decade, in part due to
rising numbers of transgenic animals and animals killed
without prior experimentation for organ and primary cell
harvesting (Kretlow et al. 2010).
Animal usage under the REACh legislation
The largest share of animals required for toxicology and
safety testing of 42% was used for acute and sub-acute
toxicity testing (Commission of the European Communi-
ties 2007). A second large fraction of 17.7% was used for
testing carcinogenicity, mutagenicity, and toxicity to
reproduction (CMR) (Fig. 6) (Commission of the European
Communities 2007). In 2003, the EU adopted the
Registration, Evaluation, and Authorization of Chemicals
(REACh) legislation. It proposes to evaluate 30,000
existing chemicals within a period of 15 years. The number
of additional animals required for toxicology and safety
testing over this period has been estimated at 9 million
(Fig. 7) (Ho ¨fer et al. 2004; European Chemicals Agency
2009). However, it has recently been suggested that this
number could become as high as 54 million (Rovida and
Hartung 2009). In 2005, testing for sub-chronic and chronic
toxicity and CMR together accounted for roughly 30% of
animals used for toxicology and safety testing. With
REACh, the share of this area will increase to about 80% of
toxicology and safety testing (Fig. 7) (van der Jagt et al.
2004). These numbers are an economic as well as an eth-
ical call for alternative methods replacing animal testing.
ZEBET has been already successfully advocating alterna-
tive methods for international acceptance at the Organi-
zation for Economic Co-operation and Development
(OECD) and continues to do so. These efforts will be
described in more detail below.
How to test for CMR and long-term organ damage
without animals?
The ﬁrst toxicological consideration is that of exposure.
Every living being has some form of barrier to protect it
from environmental stresses and impacts (Fig. 8). For the
human body, the main barriers are the skin and the mucous
Fig. 4 Areas of animal use for scientiﬁc purposes in Europe. The
charts show percentages of animal use per area according to the ﬁfth
report on the statistics on the number of animals used for
experimental and other scientiﬁc purposes in the member states of
the European Union (Commission of the European Communities
2007)
Fig. 5 Comparison of animal numbers used for scientiﬁc purposes in
Europe. Blue bars depict total animal numbers in million animals for
the 15 European member states reporting in 2002 and 2005. Orange
bars show percentages of animals used for toxicology and other safety
evaluation purposes in the 15 reporting members for 2002 and the 25
reporting states for 2005. Animal numbers are according to the ﬁfth
report on the statistics on the number of animals used for
experimental and other scientiﬁc purposes in the member states of
the European Union (Commission of the European Communities
2007)
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123membranes. The ﬁrst possible routes of exposure are
therefore skin penetration, inhalation, and exposure of the
respiratory tract, as well as ingestion and exposure of the
gastrointestinal tract. A number of in vitro models are
commercially available as three-dimensional tissue recon-
struction models (Pampaloni et al. 2009). Some examples
are epidermis, full-thickness skin models, respiratory epi-
thelia, keratinocyte eye cornea, vaginal epithelia, and oral
epithelia. Blood-tissue barriers form a second line of
defense, the most prominent of which are the blood–brain
barrier and the placental barrier; and the blood–brain bar-
rier has been modeled in vitro (Stolper et al. 2005; Cec-
chelli et al. 2007). The advance in three-dimensional
models has also allowed for internal organ models
(Pampaloni et al. 2007), such as placenta (Mess 2007),
lymph node (Giese et al. 2006), and liver (Linke et al.
2007). However, the adult human body presents with about
40 different organs composed of at least 400 cell types
(Fig. 9) (Vickaryous and Hall 2006).
To reconstruct all human tissues, in vitro would be a
formidable task today, and toxicological testing on all sep-
arate tissue models would put even the direst estimates of
animaluseinatemporallyandeconomicallyfavorablelight.
How then can we achieve an idea of the systemic toxicity of
substances without animal use? A promising approach is
computer-aided modeling of the systemic behavior of a
substance, so-called in silico methods. The physiology-
based pharmacokinetic (PBPK) model integrates informa-
tion from different in vitro and in silico quantitative
structure–activity relationship [(Q)SAR] approaches and
predicts the systemic availability of a compound under
certain exposure conditionsandhence allowstoevaluatethe
toxicological relevance of an in vitro derived toxic con-
centration (Verwei et al. 2006). An approach to predict the
target effects of a substance is the Connectivity Map
(Fig. 10) (Lamb 2007). Here, mRNA expression proﬁles are
collected in a database of a range of different cell lines
exposed to substances with known mechanisms under a
small number of deﬁned conditions. This limitation to
ubiquitous cellular pathways is a necessity since expression
proﬁles themselves are already large datasets. The expres-
sion proﬁle in response to a new substance is then compared
tothesignaturedatabase,andbysimilarityamodeofaction,
including off-target effects, can be predicted (Fig. 10).
We are still far away from a pure in vitro—in silico
approach. However, the described methods are already
Fig. 6 Areas of animal use for toxicology and safety testing in
Europe. The charts show percentages of animal use per area in 2005
according to the ﬁfth report on the statistics on the number of animals
used for experimental and other scientiﬁc purposes in the member
states of the European Union (Commission of the European
Communities 2007)
Fig. 7 Projected numbers of animals for testing under REACh in
Europe. The charts show percentages of animal use per area in 2005
compared to projected total animal usage for REACh according to
van der Jagt et al. (2004). Chronic toxicity in this chart comprises
testing for chronic, sub-chronic, and reproductive toxicity, as well as
for carcinogenicity and mutagenicity
Fig. 8 Barrier functions of the human body
Fig. 9 Composition of the human body
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123used today by the pharmaceutical industry to evaluate drug
candidates during research and development and thereby
reduce animal use in that area. A number of in vitro
methods have been accepted by the OECD or are under
review for acceptance. Computational approaches have the
same potential to drastically reduce animal use under the
REACh legislature.
Current efforts at ZEBET
Toward international acceptance of alternative methods
Already in 1990, an international committee under partic-
ipation of ZEBET convened to develop a scientiﬁc concept
for the experimental validation of toxicological testing
methods (Balls et al. 1990). Followed by two similar
workshops (Balls et al. 1995), and two OECD workshops
in 1996 and 2002 (Organisation for Economic Co-Opera-
tion, Development 1996, 2002), this ultimately led to the
OECD Guidance Document No. 34 ﬁnally ratiﬁed in 2005.
This process not only contributed to the successful vali-
dation and international recognition of alternative methods
for toxicological hazard identiﬁcation tests but also estab-
lished that the agreed principles of validation hold for any
new and updated test method, whether it is an in vivo or in
vitro method, and both for ecotoxicity tests as well as for
human health tests. In addition, this exempliﬁes the long
process of introducing new OECD guidelines, which is in
part due to the fact that a unanimous consensus has to be
found. ZEBET scientists are involved in the development
of OECD Test Guidelines (TG) and Guidance Documents
(GD), which has led to an improvement in the welfare of
laboratory animals (Table 1). An internationally harmo-
nized testing helps companies and their products to be
competitive in the global marketplace in addition to pre-
venting unnecessary repeated testing on live animals or in
vitro.
The experimental validation of any new or updated
toxicological test method requires examining both its intra-
and inter-laboratory reproducibility as well as its perfor-
mance in the prediction of toxic properties to humans. The
translation of test method readouts into human health
predictions requires prediction models which are often
based on biostatistical methods. Thus, prediction models
are crucial components of test methods as they must
guarantee correct predictions about new substances for the
purpose of human health protection. The incorporation of
the ‘‘prediction model concept’’ into GD 34 was a major
concern of ZEBET and ECVAM (Archer et al. 1997), and
probably the most important contribution to this document
through a special OECD expert consultation meeting on
‘‘Data Interpretation Procedures’’ in 2004.
Over the years, it has been understood that competent
authorities, of which ZEBET itself is a part, and stake-
holders need to be involved throughout the entire valida-
tion and acceptance process. In addition to their
participation in the national and later international con-
solidation processes (e.g., OECD, ICH, ISO), they should
be involved already in earlier steps. The deﬁnition of their
information needs and identiﬁcation of suitable readouts
and endpoints of the new method, the selection of suitable
tests and test chemicals, and subsequently the peer review
of the method all beneﬁt from their involvement, and
Fig. 10 Schematic
representation of the principle
of the connectivity map. Data
on the cellular response to
known substances are collected
using several proﬁling methods
such as proteomics and
transcriptomics. The results are
combined in an interaction map,
the connectivity map. The
cellular response proﬁle of an
unknown substance is compared
to the connectivity map and a
mechanism of action deduced
from similarities to proﬁles of
known substances
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123importantly help to avoid the development of tests not
suitable to support regulatory decisions. In later stages,
regulators should be involved in the deﬁnition of perfor-
mance standards and the deﬁnition of special studies, e.g.,
to enlarge the applicability domain of a new test method
which can also mean the extension of regulatory accep-
tance into new areas not yet validated.
This lesson was learned during the evaluation of the
Corrositex assay for skin corrosion (Interagency Coordi-
nating Committee on the Validation of Alternative Meth-
ods 1999). The test producer used a panel of chemicals
during development that mostly covered pH values \3o r
[11, substances which would be suspected as corrosive by
that fact alone. Indeed, chemical categories with a majority
of chemicals providing extreme pH values have been
ﬁnally accepted to be the validated applicability domain of
the Corrositex assay, and it is therefore now instrumental
for hazard sub-categorization of corrosive chemicals and
products in the context of UN regulations for transportation
of dangerous goods.
Similarly, at the heart of the idea of performance stan-
dards for test guidelines was the acute problem of loss of
suppliers for two human reconstituted skin models during
their early validation for testing for skin corrosivity (Balls
1997). Performance standards deﬁne global criteria that a
test method is expected to fulﬁll, independent of a speciﬁc
test setup. To emphasize the importance of performance
standards, we may look at the achievements in the auto-
mobile industry. When renting a car of unknown make at
an airport nowadays, due to standardization, we are
familiar with the instruments and are able to safely drive
within a few minutes without the need of a manual and
further advice. Most importantly, we can trust that in a
dangerous situation, the car will behave similar to other
cars; for instance, due to internationally agreed perfor-
mance standards, braking distances of today’s cars are in
the range of 40 m ± 7% when coming to a halt from a
speed of 100 km/h. Translated into the area of new toxi-
cological test guidelines, this means that deﬁnition of
performance standards in the test guidelines will allow for
so-called catch-up validation. For instance, the OECD TG
431 deﬁnes general and functional conditions that an in
vitro human reconstructed (dermal or epidermal) model
must meet before it can be used routinely for skin corrosion
testing. In addition, the guideline requires correct predic-
tion of twelve reference chemicals as well as assessment of
intra- and inter-laboratory variability. This allows new
developments or very similar assay systems to be rapidly
incorporated into guidelines. For example, the SkinEthic
RHE in vitro corrosion test was accepted by ECVAM little
Table 1 OECD test methods that have been improved in respect to animal welfare under participation of ZEBET
Complete replacement of the animal experiment
TG 428 Skin absorption: in vitro method
TG 430 In vitro skin corrosion: transcutaneous electrical resistance (TER)
TG 431 In vitro skin corrosion: human skin model test
TG 432 In vitro 3T3 NRU phototoxicity test
TG 437 Bovine corneal opacity and permeability test method for identifying ocular corrosives and severe irritants
TG 438 Isolated chicken eye test method for identifying ocular corrosives and severe irritants
TG 439 In vitro skin irritation: reconstructed human epidermis (RhE) test method
Reduction in the number of animals and stress of the laboratory animals
TG 420 Acute oral toxicity—ﬁxed dose procedure
TG 423 Acute oral toxicity—acute toxic class method
TG 425 Acute oral toxicity—up-and-down procedure
TG 429 Skin sensitization—local lymph node assay
TG 436 Acute inhalation toxicity—acute toxic class method
The following OECD guidance documents have been developed or improved from the animal welfare perspective
GD 14 Detailed review document on classiﬁcation systems for eye irritation/corrosion in OECD member countries
GD 16 Detailed review document on classiﬁcation systems for skin irritation/corrosion in OECD member countries
GD 19 Guidance document on the recognition, assessment, and use of clinical signs as humane endpoints
GD 24 Guidance document on acute oral toxicity testing
GD 28 Guidance document for the conduct of skin absorption studies
GD 34 Guidance document on the validation and international acceptance of new or updated test methods for hazard assessment
GD 39 Guidance document on acute inhalation toxicity testing
GD 69 Guidance Document on the validation of (quantitative) structure–activity relationship [(Q)SAR] models
GD 105 Report on biostatistical performance assessment of the draft TG 436 acute toxic class testing method for acute inhalation toxicity
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123more than half a year after publication of its catch-up
validation study (Kandarova et al. 2006; European Center
for the Validation of Alternative Methods 2006). The more
recent TG 439 comprises three elements for performance
standards, essential test method components, a minimum
list of twenty reference chemicals, and deﬁned reliability
and accuracy values. The latter values represent the sen-
sitivity, speciﬁcity, and accuracy of current methods, and
any new method has to perform equal or better.
ZEBET is also in the unique position to be able to
perform ‘‘horizontal’’ method re-evaluation. A study
investigating the necessity for the use of one rodent and
one non-rodent animal species, usually rats and dogs, in
parallel for repeated dose toxicity of pesticides revealed
that treatment of dogs for longer than 90 days provides no
additional information indispensable for risk assessment
(Spielmann and Gerbracht 2001; Box and Spielmann
2005). This was possible since ZEBET had access to reg-
ulatory data covering 40 years of authorization of pesti-
cides from companies supplying Germany through the
competent regulatory authority (BGA and later BgVV). At
ZEBET, such data, which is in most cases not published
and conﬁdential, can be analyzed anonymously.
Another example of the scientiﬁc use of proprietary
data for the development of an in silico prediction tool is
the development of the ‘‘decision support system’’ for
skin irritation and corrosion. Based on the conﬁdential EU
New Chemicals Database, a set of exclusion rules derived
from physicochemical properties and structural alerts
derived from SAR models were developed at the BGA
(and later BgVV) in cooperation with the Dutch Ministry
of Health (RIVM) and the US-Environmental Protection
Agency (US-EPA) for identifying chemicals that are
unlikely or likely to cause skin irritation or corrosion
(Gerner et al. 2004; Hulzebos et al. 2005; Walker et al.
2004, 2005). This in silico method is recommended to be
used within the new EU regulation of chemicals (REACh)
and is currently integrated in the OECD (Q)SAR Appli-
cation Toolbox.
The use of embryonic stem cells in developmental
toxicity testing
Congenital abnormalities represent perhaps the most severe
side effects a chemical can have, and their prevention is an
essential goal in toxicological safety assessment of chem-
icals and drugs. To evaluate adverse effects on reproduc-
tion and embryonic development, mandatory OECD test
guidelines, or so-called segment studies, encompassing
three crucial periods of pre- and postnatal development and
fertility have been established (International Conference on
Harmonisation of Technical Requirements for Registration
of Pharmaceuticals for Human Use 2005a). These
guidelines specify time-consuming and expensive in vivo
experiments mostly performed on mammalian species such
as rats or rabbits (Fig. 6).
Over the past 30 years, a wide spectrum of in vitro
models has been developed to detect teratogenic effects of
chemicals. These test systems either utilize whole embryos
or dissociated cells from embryos (Piersma 2006). In
recent years, stem cells have been the subject of increasing
scientiﬁc interest because they represent an important new
tool for developing unique in vitro model systems. They
also have great potential to predict or anticipate com-
pound-triggered toxicity in vivo. Stem cells are capable of
self-renewal, that is, they can be continuously cultured in
an undifferentiated stage, giving rise to more specialized
cells such as heart, liver, bone marrow, blood vessels,
pancreatic islets, and nerve cells upon addition or removal
of certain growth factors [Fig. 11, reviewed in (Hoffman
and Merrill 2007)]. In 1997, ZEBET developed an in vitro
model for screening of embryotoxicity based on blasto-
cyst-derived embryonic stem cells from mice (mESC).
This so-called embryonic stem cell test [EST; (Spielmann
et al. 1997; Seiler et al. 2006a)] is based on the assessment
of three toxicological endpoints: (1) the morphological
analysis of beating cardiomyocytes in embryoid body
outgrowths compared to cytotoxic effects on, (2) mESC,
and (3) 3T3 ﬁbroblasts (Fig. 11). As an in vitro system
which mirrors both proliferation and differentiation, the
EST proved in an international European Centre for the
Validation of Alternative Methods (ECVAM) validation
study to be a reliable assay for the prediction of embryo-
toxicity in vivo (Genschow et al. 2004). Using a set of 20
reference compounds with different embryotoxic potencies
(non-embryotoxic, weakly embryotoxic, and strongly
embryotoxic), the EST was shown to provide a correct
judgment in 78% of all experiments. Remarkably, a
predictivity of 100% was obtained for strong embryotox-
icants. As a consequence, the validated EST has been
accepted and successfully introduced by many pharma-
ceutical companies as a tool for testing the developmental
toxicity of lead compounds at an early stage in R&D
toward new drug candidates (Paquette et al. 2008; Whitlow
et al. 2007).
One prominent drawback of the classical EST, which is
shared by other in vitro assays for embryotoxicity such as
the whole embryo culture test and the rat limb bud
micromass test, is its reliance on a morphological endpoint.
Although all of these tests systems offered 100% predici-
tivity for strong embryotoxicants as veriﬁed in the ECVAM
validation trial, it is of great concern that they all rely on
experienced laboratory personnel to produce high-quality
data (Spielmann et al. 2006). In order to improve the
accuracy of these assays, we and other research groups are
now focused on the identiﬁcation of novel molecular
Arch Toxicol (2011) 85:841–858 847
123endpoints to be assessed by more objective and quantitative
means, such as gene expression analysis based on real-time
RT-PCR and ﬂow cytometry (Seiler et al. 2004; zur Nieden
et al. 2004). In a recent study, we worked out a new
molecular approach based on the analysis of the expression
of certain marker proteins speciﬁc for developing heart
tissue (i.e., sarcomeric MHC and a-actinin) using quanti-
tative ﬂow cytometry analyses (Fig. 11). The molecular
FACS-EST offered the same sensitivity compared to the
validated EST protocol but the test duration could be
signiﬁcantly reduced. Due to these improvements, this new
molecular method holds promise as a sensitive, more rapid
and reproducible screen highly suited to predict develop-
mental toxicity in vivo from in vitro data (Buesen et al.
2009). Recent studies on glycol ether alkoxy acid metab-
olites (de Jong et al. 2009) and valproic acid derivatives
(Riebeling et al. 2011) nicely demonstrated that both the
standard EST and the molecular FACS-EST can be reliably
used as a tool to assess structure-dependent teratogenicity.
Currently, the stem cell research group at ZEBET is
committed to exploring and developing additional stem
cell-based approaches, searching for novel predictive bio-
markers of developmental toxicity, and extending the
experimental approach to other cellular systems for the
prediction of developmental neuro- and osteotoxicity.
Promising differentiation protocols for certain cell types
most susceptible to chemical-mediated toxicity during
early development like cardiac, bone, and neural cells have
been successfully developed. For neural cell development,
we could demonstrate that mouse embryonic stem cells can
be efﬁciently differentiated in vitro into cell types present
in the nervous system like mature neurons, astrocytes, and
oligodendrocytes (Seiler et al. 2006b). On the basis of this
approach, new rapid and predictive in vitro screens for
developmental neurotoxicity testing have been developed.
Currently, investigations are underway to explore the use
of pluripotent stem cell lines derived from primate blas-
tocysts in assessing developmental osteotoxicity. Due to
the close evolutionary relationship, these cells might help
to improve the predictivity for human toxicity.
Recently, new exciting avenues of research on the role
of microRNA (miRNA) in toxicogenomics and the possi-
bility of epigenetic effects on gene expression were iden-
tiﬁed. Therefore, miRNA proﬁling opens the possibility to
discover new molecular endpoints that might contribute to
a further understanding of chemical-mediated develop-
mental toxicity. Current investigations are aimed at
studying miRNA expression in differentiating mouse
embryonic stem cells and their dysregulation upon expo-
sure to embryotoxic compounds. Furthermore, in line with
the report from the National Research Council on toxicity
testing in the twenty-ﬁrst century, which has proposed
fundamentally new directions for toxicity testing in light of
advances in understanding biological responses to chemi-
cal stressors (Krewski et al. 2010), new research projects at
ZEBET involve the mapping of toxicity pathways in
differentiating mouse and human stem cells as well as
pluripotent stem cell lines and the identiﬁcation of critical
pathway perturbations that either correlate with or directly
represent molecular initiation events for adverse effects
during human embryonic development.
Implementing the 3Rs principle by funding
the development of alternative methods
An increasing demand for health risk assessment due to
the REACh program of the EU, as well as changes in the
legislature exempliﬁed by the 7th Amendment of the
Cosmetics Directive that prohibits the use of animal
experiments for the toxicological evaluation of cosmetic
ingredients, has stimulated the search for novel experi-
mental approaches that have the potential to reduce or
replace animal experiments.
The EU responded to these needs and joined with the
cosmetic industry to establish a €50 million research pro-
gram as part of the 7th EU framework program for the
Fig. 11 Using embryonic stem cells for embryotoxicity testing.
a Embryonic stem cells have the potency to differentiate into all cell
types of the body. b Schematic representation of the validated
embryonic stem cell test (EST) for embryotoxicity testing. c Modi-
ﬁcation of the EST to broaden its applicability domain using
molecular endpoints
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123development of alternative test methods in the ﬁeld of
repeated dose systemic toxicity. A survey conducted in
2006–2007 estimated the total funding of 16 participating
European countries at about €17 million (Devolder et al.
2008). The total funding in Germany was estimated at
€4.6 million, mainly due to the ‘‘Alternatives to Animal
Testing’’ program of the Federal Ministry of Education and
Research (BMBF) that has been already established in
1980 (Bundesministerium fur Bildung und Forschung
2001). In Germany, this is the only program that provides
sufﬁcient ﬁnancial support for the cost-intensive and time-
consuming process of validation. In addition, several fed-
eral states, including Baden-Wuerttemberg (http://www.
mlr.baden-wuerttemberg.de), Hessen (http://www.hmulv.
hessen.de), and Rheinland-Pfalz (http://www.mufv.rlp.de),
as well as the private Foundation for the Promotion of
Alternate and Complementary Methods to Reduce Animal
Testing (SET; http://www.tierversuche-ersatz.de), and
ZEBET@BfR support such research projects, although
with much more limited resources (Fig. 12).
On the other hand, the US National Academy of Sci-
ences published its vision of a modern toxicology in the
twenty-ﬁrst century in 2007 (Krewski et al. 2010). The US-
EPA, the NIEHS National Toxicology Program, and the
National Institutes of Health Chemical Genomics Center
joined forces to follow this ambitious proposal to develop
new toxicity testing strategies, with an emphasis on high
throughput technologies to establish toxicological
‘‘ﬁngerprints’’ or reveal toxicological pathways of chemi-
cals, complex mixtures, and pharmaceuticals (Krewski
et al. 2009, 2010; Dix et al. 2007; Andersen and Krewski
2009).
These more recent activities reﬂect a completely chan-
ged perception of alternative and in vitro methods as a tool
for toxicological risk assessment. Following the imple-
mentation of the EU Directive 86/609 and the revision of
the German animal welfare act, promoting the develop-
ment of alternative methods became one of the main
missions of ZEBET. Since its inception, ZEBET supports
research projects throughout Germany which have the
potential to provide novel and innovative experimental
approaches to reduce or replace animal experiments with a
unique funding program (Fig. 12).
The ﬁnancial resources of ZEBET@BfR allow for the
support of approximately ten projects at a time, amounting
to over 100 funded research projects over the last 20 years
(Fig. 12). The emphasis is given to projects that lack the
experimental evidence that is necessary to seek ﬁnancial
support from larger funding agencies but target important
regulatory needs and appear promising to contribute sub-
stantially to animal welfare. In this respect, the integration
of ZEBET into the BGA ﬁrst and the BfR later proved
instrumental, since the close proximity to regulators facil-
itated the exchange of information concerning regulatory
needs and thus the selection of meaningful projects at the
right time.
Over a period of 2–3 years, the investigator is provided
with sufﬁcient funds to gather experimental evidence in
proof-of-concept studies. For example, the establishment of
recombinant Chinese hamster V79 cell lines ectopically
expressing human cytochrome P450 enzymes allowing the
analysis of drug metabolism and toxicity led to subsequent
funding by the BMBF and EU and the successful founda-
tion of a company (Do ¨hmer 2001). In addition, the devel-
opment of bioreactors enabled scientists to avoid the use of
ascites as a source for monoclonal antibodies and are now
used to simulate various organs, including the human
lymph node, to evaluate the sensitization potential of
chemicals or pharmaceutical substances (Giese et al. 2006).
Furthermore, initial work on the development of the
monocyte activation test as an alternative to pyrogen test-
ing in rabbits was supported by the ZEBET and will be
adopted by the European Pharmacopoeia (Hartung et al.
2001).
ZEBET@BfR also funded the development of various in
silico methods based on structural similarities that gained
increasing importance over the last years in the evaluation
of potential adverse effects, but also for the analysis of in
vitro data. For example, the lazy structure–activity rela-
tionships (LAZAR) program is used to predict genotoxic
activities of chemicals based on structural similarities to
Fig. 12 Research funding at ZEBET@BfR. Charts show a the funds
available to ZEBET@BfR for funding research and b the number of
projects funded by ZEBET@BfR since the inception of ZEBET
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Similarly, ZEBET provided the ﬁnancial support to allow
the development of software required for the prediction of
the phototoxic potential of chemicals based on the results
obtained by the in vitro 3T3 NRU phototoxicity test
(OECD TG 432), and the biometric evaluation of the Acute
Toxic Class (ATC) method for acute inhalation toxicity
(OECD TG 436). These projects were essential to achieve
international acceptance of these methods as OECD test
guidelines (Holzhu ¨tter 1997; Holzhu ¨tter et al. 2003). Fur-
ther, the establishment of the so-called Registry of Cyto-
toxicity that is based on published data from hundreds of in
vitro cytotoxicity assays provides strong evidence that the
in vivo toxicity of chemicals can be predicted from in vitro
data (Halle 2003). This in turn can have a signiﬁcant effect
on the number of animals used for in vivo toxicity testing,
e.g., by facilitating the calculation of the starting dose for
acute oral toxicity studies. Finally, in silico models that
provide important information concerning the permeability
of the human skin have been developed that correlate well
with results obtained using in vitro experimental skin
models (Hansen et al. 2008).
A large number of cell-based, organotypic or ex vivo
approaches were supported over the years, including
models for speciﬁc toxicological effects on liver, heart,
lymph node, ovary, ear, central nervous system, cornea, or
the skin (Fig. 9). In particular, the use of human skin
models was promoted by ZEBET. As an in vitro alternative
to the rabbit test for skin irritation and corrosion (OECD
TG 404), this model is now accepted worldwide. In addi-
tion, these models are very useful for the prediction of skin
adsorption and penetration of chemicals and pharmaceuti-
cals (Scha ¨fer-Korting et al. 2008).
In summary, the support by ZEBET of a broad spectrum
of activities and ideas was very successful in promoting the
development of in vitro systems that already reduce or
replace animal experiments or bear the promise to con-
tribute to the 3Rs concept in the near future. The success of
the ZEBET@BfR funding program is also reﬂected by the
various national and international awards received by the
funded scientist for their work and contributions to the 3Rs
as summarized in the brochure published by the BfR on the
occasion of the 20th anniversary of ZEBET (http://www.
bfr.bund.de/cd/30995).
ZEBET’s competence in searching for literature
and information on alternative methods to animal
experiments
Acknowledging that ‘‘man has a moral obligation to
respect animals and to have due consideration for their
capacity for suffering’’ (Council of Europe 2005), the EU
has stipulated legislation to protect animals that are used
for experimental and other scientiﬁc purposes (Council of
Europe 2005).
As a consequence, in addition to morality, there is a
legal obligation to identify and use appropriate methods to
replace, reduce, or reﬁne experimental animal use. This
obligation considers the internationally accepted 3Rs
concept that was laid out by Russel and Burch in 1959.
Concerning replacement, an ‘‘experiment shall not be
performed if another scientiﬁcally satisfactory method of
obtaining the result sought, not entailing the use of an
animal, is reasonable and practicably available’’ (Council
of Europe 2005). Furthermore, as to reduction and reﬁne-
ment experiments which ‘‘use the minimum number of
animals, involve animals with the lowest degree of
neurophysiological sensitivity, cause the least pain, suf-
fering, distress, or lasting harm’’ should be selected
(Council of Europe 2005). Therefore, the search for rele-
vant information about methods compliant with the 3Rs is
a key issue of authorization procedures for animal experi-
ments in Europe.
Scientists in the European countries planning to conduct
animal experiments are obliged to undertake a valid
‘‘indispensability search’’ prior to applying for an autho-
rization of the experiment at the national competent
authority. The aim of an indispensability search is to proof
the lack of the presence of (1) a suitable alternative method
according to the 3Rs concept that can be applied instead,
(2) usable results from comparable previous animal
experiments, and (3) results from other research suited to
anticipate the outcome of the planned experiment. Only
when the availability of a suitable alternative or of usable
scientiﬁc results have been excluded based upon the cur-
rent state of knowledge, an animal experiment may be
authorized.
Scientiﬁcally relevant databases like PubMed provide
the opportunity to search an ever-growing number of
documents simultaneously via simple and usually general
keywords. After retrieving the hit list, extensive efforts are
usually required for sorting out irrelevant literature.
Moreover, the typical curriculum of scientists completely
lacks courses in information retrieval. Most scientists may
only be capable of applying ordinary searcher skills. In the
ﬁeld of patent affairs, where the ‘‘novelty search’’ has a
similar signiﬁcance, it is estimated that the cost of dupli-
cate research due to irrelevant information retrieval
amounts to about €20 billion a year in Europe alone
(European Patent Ofﬁce 2009).
In order to support the implementation of animal pro-
tection obligations in the sciences, ZEBET advises indi-
vidual scientists and authorities how to obtain, evaluate,
and apply information on suitable alternative methods.
ZEBET follows a three-fold strategy to improve infor-
mation dissemination on alternative methods to animal
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with information, (2) education in reliable search proce-
dures, and (3) research in retrieval technology.
AnimAlt-ZEBET: all the essential information
in a nutshell
Evaluation of value-added databases represents the most
reasonable starting point for any structured search for
information (Emmerich 2009). At the forefront of these
essential resources is the AnimAlt-ZEBET database hosted
by the German Institute of Medical Documentation and
Information (DIMDI), accessible online free of charge
(Fig. 13; http://www.dimdi.de/static/en/db/dbinfo/zt00.htm).
The documents in the database are written in a structured
and standardized manner and focus on the most essential
facts of the listed alternative methods. The added value of
these documents is constituted through expert selection of
the incorporated literature, committed to the most sub-
stantial and reliable information only, and a subsequent
stringent peer review process including scientists with
complementing in vivo and in vitro expertise. Composition
and phrasing of the method summaries are standardized to
enable immediate orientation and easy comprehension, and
to provide the possible feedstock for up-to-date text mining
applications. To obtain a general idea on the method at
hand, the reader simply can consult the meta-data ﬁelds
‘‘Title’’, ‘‘Evaluation’’, ‘‘Status’’, and ‘‘Regulation’’, in
combination with the abstract section ‘‘3R relevance’’.
Here, users will ﬁnd highlighted facts to consider, the
speciﬁc objective that can be addressed by employing the
method at hand, the state of development, its acceptance in
the scientiﬁc and regulatory communities, its application
domain, and its contribution to the 3Rs concept. The main
text of the method summary aims to cover all aspects
necessary for understanding the suitability and applicabil-
ity of the method with a focus on practical considerations.
The section ‘‘Expert Panel Opinions’’ provides a detailed
picture on the acceptance of the particular approach and
possible objections by ofﬁcial bodies.
In the basic sciences, the impact of a method is judged
by bibliometric analyses, i.e., citation analyses and the
impact factor of the publishing journal. For a more
informed evaluation, it is planned to conduct expert con-
sultations whenever a sufﬁcient body of alternative meth-
ods addressing a deﬁned topic in the basic sciences has
been compiled. The primary objective of the consultations
will be to reach consensus on the relevance and the fore-
seen application domains of the given methods.
Currently, the emphasis of the database is on methods in
toxicity and potency testing, e.g., alternatives in skin sen-
sitization, eye irritation, or Botulinum neurotoxin potency
testing. In the future, the focus will be extended to cover
alternatives in the basic sciences more comprehensively.
Accordingly, the latest method portraits feature alternatives
to animal models in neurodegenerative processes, such as
traumatic brain injuries, and Parkinson’s and Alzheimer’s
disease.
Education in reliable search procedures
Surveying the relevant literature is part of the daily busi-
ness in basic science and medicine; however, courses on
information retrieval are not obligatory in scientiﬁc edu-
cation. In cooperation with the universities and the
Regional Authority for Health and Social Matters of Berlin
(LAGeSo), ZEBET@BfR contributes to training courses
on ‘‘Laboratory Animals, Animal Experiments and Alter-
natives’’. This course is certiﬁed by the German Society for
Laboratory Animal Science (GV-SOLAS) and is attended
by some 200–300 scientists involved in animal experi-
mentation per year. The ZEBET part covers topics of
information retrieval like structured searching, choosing
the most relevant information resources, conceiving of
search terms, using operators and wildcards, index-term-
based searching, and semantic search engines. A main goal
of the course is to instruct participants in index-term-based
(classiﬁcation) searching strategies (Motschall and Falck-
Ytter 2005), and 3R-relevant terms.
In addition, ZEBET cooperates with ECVAM of the
European Commission’s (EC) Joint Research Centre (JRC)
in developing a search guide primarily to support scientists,
regulators, and ethical committees involved in the plan-
ning, ethical review, authorization, and conduct of animal
experiments.
Research in retrieval technology
Search engines that integrate human expert domain
knowledge are a subgroup of ‘‘semantic search engines’’.
They aim to gather the meaning of natural language doc-
uments or phrases from the occurrence and co-occurrence
of certain terms and their synonyms within the text of a
document and thus assist scientists in retrieving and sorting
relevant domain literature.
The Go3R tool aids in retrieving 3R-relevant literature
from PubMed (Fig. 14) (Sauer et al. 2009). It is the
worldwide ﬁrst tool of its kind specially equipped with
expert domain knowledge from the area of the 3Rs. This
knowledge is captured within a so-called ‘‘ontology’’, i.e.,
an extensive and detailed network of ‘‘concepts’’, terms
that are unambiguous identiﬁers of a scientiﬁc domain such
as ‘‘gene chip’’ in the ﬁeld of genetic high-throughput
screening, or ‘‘humane endpoints’’ in the ﬁeld of the 3Rs.
When a user performs a search query with Go3R, the
search engine compares the concepts of the ontology with
Arch Toxicol (2011) 85:841–858 851
123the vocabulary used in the retrieved documents (Sauer
et al. 2009). It highlights relevant terms or their synonyms
and uses them to arrange the documents within an ‘‘intel-
ligent’’ directory of contents. The Go3R tool has been
developed by scientists from the Technical University of
Dresden and the Transinsight GmbH (Dresden, Germany)
in cooperation with ZEBET, the chemical company BASF
SE (Ludwigshafen, Germany), and the Scientiﬁc Consul-
tancy—Animal Welfare (Neubiberg, Germany). The beta-
Version is available online free of charge (Fig. 14;
http:\\www.Go3R.org). To date, it contains about 17,000
concepts structured in 26 branches with biomedical head-
ings, such as ‘‘Cell Culture Technology’’, and ‘‘3Rs
Methods in the Life Sciences’’. A current effort to improve
the Go3R tool by re-engineering and expansion is funded
by the BMBF. An essential extension will be the inclusion
of scientiﬁc resources other than PubMed. The ultimate
aim is to open up resources that right now are non-acces-
sible to an indispensability search due to their non-indexed
and/or unstructured nature. Go3R thus may be used to
assign 3R-relevant index-terms to unstructured natural
language documents in retrospect automatically.
Advisory services for public authorities, ministries,
and scientists
Over the last 20 years, ZEBET has developed an impres-
sive expert knowledge on alternative methods. In line with
the 3Rs principle, ZEBET’s main priority is to reduce the
number of laboratory animals to the absolutely necessary
minimum, to reﬁne experimental procedures and housing
of animals, to minimize pain and suffering and, if possible,
to replace animal experiments with alternative methods.
ZEBET staff members share their knowledge with scien-
tists, competent authority staff, animal welfarists, and other
interested persons in a number of ways. Research institutes,
competent authorities, and individuals can submit direct
inquiries about alternative methods according to the 3Rs
principle to ZEBET in addition to the aforementioned
Fig. 13 The AnimAlt database
hosted at DIMDI. AnimAlt-
ZEBET is a full text database of
evaluated alternative methods to
animal experiments in
biomedicine and related ﬁelds
developed by ZEBET
Fig. 14 The Go3R tool for retrieving 3R-relevant literature from
PubMed. The Go3R tool has been developed by scientists from the
Technical University Dresden and the Transinsight GmbH in
cooperation with ZEBET, the chemical company BASF SE and the
Scientiﬁc Consultancy—Animal Welfare and is funded by the
German Federal Ministry of Education and Research (BMBF)
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average 450–600 individual inquiries per year. A proﬁle of
ZEBET’s customers for the year 2008 is shown in Fig. 15.
The Federal Ministry of Food, Agriculture and Con-
sumer Protection (BMELV) is responsible for consumer
protection and animal welfare in Germany. ZEBET as part
of the BfR, which is a higher federal authority, is directly
reporting to the BMELV. Consequently, ZEBET advises
the ministry’s animal welfare division on all scientiﬁc
questions of animal welfare in the context of laboratory
animals. For instance, ZEBET experts repeatedly advised
the BMELV in conjunction with the amendment of EU
Directive 86/609 which regulates the handling of labora-
tory animals in the EU.
Furthermore, ZEBET scientists examine on request of the
competentauthoritiesofthefederalstates(‘‘La ¨nder’’)whether
an animal experiment for which an application has been
submittedisindispensable pursuanttothe animal welfareact.
For this assessment, more than 250 scientists at the BfR and
also scientists at other federal institutions can be consulted in
the evaluation. ZEBET scientists investigate whether the
application reﬂects the latest scientiﬁc ﬁndings, whether
alternative methods exist that can be used instead of the pro-
posed animal experiment, whether the experimentaldesign is
statistically sound and, at the same time, whether the number
of animals reduced to a minimum without compromising the
objectivesoftheproject.Additionally,scientistswhodevelop
or wish to establish new alternative methods in research
institutes, universities, or industry also frequently approach
ZEBET. Because of their many years of experience in the
development, validation, and regulatory recognition of alter-
nativemethods,ZEBETscientistsareabletojudgewhethera
new alternative method is likely to be a suitable replacement
for aninternationally establishedanimal experimentand how
thisgoalmightbeachieved.ZEBETscientistsarealsosought
as experts on the international level in research support pro-
grams for the development of alternative methods and for the
judging of research prizes.
Furthermore, ZEBET scientists are very popular inter-
view partners for the German media because of their
comprehensive expert knowledge.
Regulatory challenges to be urgently addressed:
The example of Botulinum neurotoxin
Botulinum neurotoxin (BoNT) is a biological product
released by the anaerobic, gram-positive bacterium Clos-
tridium botulinum. There are seven major and serologically
distinct serotypes of BoNT, characterized by a complex
mode of action which results in a blockade of acetylcholine
release at neuro-muscular nerve endings leading to ﬂaccid
paralysis (Fig. 16). This mechanism of toxicity comprises
at least three stages of binding, internalization, and prote-
olytic cleavage of a substrate, which leads to inhibition of
synaptic exocytotoxic transmitter release. Different sero-
types of BoNT act on different substrates.
Currently, the serotypes BoNT-A and BoNT-B are used
as active ingredients in licensed drugs for the treatment of a
variety of medical disorders such as cervical dystonia,
blepharospasm, spastic conditions, and hyperhidrosis.
However, BoNT is also used in so-called ‘‘esthetic medi-
cine’’ to temporarily treat facial asymmetries or reduce
facial lines. BoNT’s pharmacological activity is extraor-
dinarily high which, due to its biological origin, varies
from batch to batch. Therefore, it is not only a question of
potency but also of drug safety that the biological activity
of BoNT needs to be determined as accurately as possible.
The monograph ‘‘Botulinum Toxin Type A for Injection’’
of the European Pharmacopoeia 7.2 (Council of Europe
2011) states that every production lot of BoNT has to be
tested in an LD50 potency test in mice (Fig. 16), where the
ﬁnal dilution series results in the highest dosing killing
90% of animals and the lowest dosing in at least 90%
survival.
In the case of BoNT LD50 potency testing, the dosing of
animals is associated with severe suffering. Death is gen-
erally secondary to respiratory failure due to paralysis of
the respiratory muscles. Consequently, the introduction
of alternative methods is urgently required. A number of
alternative tests have been developed in the past decades
aiming to replace the mouse bioassay. Additionally,
promising methods are under development, which may
alone or in combination with other assays meet the rigid
requirements of potency testing.
The basis for successful validation studies for alternative
bioassays is the International Conference on Harmonisation
of Technical Requirements for Registration of Pharma-
ceuticals for Human Use (ICH) guideline Q2 (Validation of
analytical procedures) (International Conference on Har-
monisation of Technical Requirements for Registration of
Pharmaceuticals for Human Use 2005b). Since the LD50
tests of the different BoNT-producing companies vary and
are product speciﬁc (Mclellan et al. 1996; Sesardic et al.
2003), the speciﬁc alternative methods have to be validated
for each individual medicinal product. In this context, no Fig. 15 Client proﬁle of ZEBET@BfR in 2008
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validation plans have to be developed.
Ethical concerns have been raised in both Europe and
the US about the animal suffering in BoNT potency testing,
especially in the context of BoNT’s cosmetic applications.
As a result, the BMELV commissioned ZEBET to assess
the status of the different existing alternative methods to
the BoNT LD50 potency test and the most promising
approaches for their validation. In the following, an Expert
Meeting on the ‘‘Current Scientiﬁc and Legal Status of
Alternative Methods to the LD50 Test for Botulinum
Neurotoxin (BoNT) Potency Testing’’ was held at the BfR
on April 27–28, 2009 (Adler et al. 2010). Experts from
industry, regulatory authorities, German ministries, aca-
demia, national and international validation centers, and
animal welfare organizations were invited to actively par-
ticipate in the meeting.
During the meeting it became clear that guidance on
product-speciﬁc validation of alternative methods to the
LD50 potency test needs to be given by the regulatory
authorities in close communication with the manufacturers
before and during the validation process. To facilitate
validation efforts, international harmonization and mutual
acceptance criteria of regulatory authorities are necessary.
Importantly, funding should be made available and coor-
dinated to develop and validate alternative assays for
BoNT potency testing according to the 3Rs principles.
Especially the development of a replacement alternative for
BoNT testing should have priority.
At the expert meeting, researchers and industry could
demonstrate some progress in implementing reduction and
reﬁnement in BoNT potency testing, and in the develop-
ment of alternative potency assays. Still, the majority of
participants expressed the wish that a ‘‘BoNT Expert
Working Group’’ (BoNT EWG) should be established in
order to provide advice and guidance on validation
requirements for proposed alternative methods and to
deﬁne minimum standards in order to implement the 3Rs in
BoNT potency testing. Furthermore, the BoNT EWG
should promote awareness and transparency between the
stakeholders and regulatory authorities. By request of the
participants of the meeting, ZEBET@BfR in collaboration
with the Federal Institute for Drugs and Medical Devices
(BfArM) accepted to function as chairs and coordinators of
this working group.
The BoNT EWG comprises experts from European
regulatory authorities, 3R-related and validation institu-
tions, manufacturers, and scientists. Additionally, experts
from overseas are invited as observers. It will meet regu-
larly several times per year during a proposed time frame
of 4 years. The BoNT EWG has been formally established
and their statutes phrased and adopted in three meetings so
far. However, the outcomes of the meetings remain conﬁ-
dential unless otherwise expressly agreed by all members.
Future perspectives
Although much has been achieved in the past 20 years, and
in the 50 years since Russell and Burch’s seminal book
phrasing the 3Rs (Russell and Burch 1959), many areas
involving experimental animals have been barely touched
Fig. 16 Botulinum neurotoxin testing. a Botulinum neurotoxin acts
at the molecular level by proteolysis of factors involved in vesicle
docking at the neuromuscular junction. ACh, acetylcholine; BoNT,
Botulinum neurotoxin; Syntaxin, VAMP, and SNAP25 are proteins
involved in vesicle tethering at the plasma membrane which are the
targets of different Botulinum neurotoxins. b As described in the
regarding monograph of the current European Pharmacopoeia, BoNT
produced for medical applications has to be tested for potency at
several steps during production
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advancement of science. Therefore, our future efforts have
to go beyond improving and extending what is already
established, both regulatorily and experimentally (cf.
above; Table 2).
With the realization that testing and experimentation on
animals will be indispensable for some time to come grows
the importance of the aspect of reﬁnement (Fig. 1;
Table 3). BfR’s capacity in animal experimentation
should be employed to establish a ‘‘reﬁnement center’’ at
ZEBET@BfR. Research into reﬁnement is still on the
sideline, but it has been shown already that enriched
environments for laboratory animals improve the reliability
of test results (Cao et al. 2010; Glaser and Kiecolt-Glaser
2005). Again, ZEBET’s ability in funding and fostering
collaborations can play a pivotal role in enhancing this
area. Most importantly, it would allow for training of
veterinary surgeons and staff involved in animal experi-
mentation, which will ideally become a mandatory part of
their curriculum. In this respect, a severity classiﬁcation of
procedures on animals could be established in accordance
to the new European Directive 2010/63/EU of the Euro-
pean Parliament and of the Council on the protection of
animals used for scientiﬁc purposes which would function
as a guide for people involved in all stages of planning,
writing, and execution of animal experiments. In Septem-
ber 2010, the European Parliament adopted the revised
Directive on the protection of animals used for scientiﬁc
purposes. The new Directive will take effect on January 1,
2013 (Directive 2010). Until then, the Member States have
time to implement the Directive 2010/63/EU into national
legislation (Directorate General for the Environment 2010).
However, building on our strengths, such as boosting
collaborations and networking in the national as well as the
international arena, and intensifying our efforts at the
OECD level, will remain a central future aim. Also, the
existing expertise in in vitro methodologies as alternatives
to animal testing needs to be fairly expanded, and research
efforts especially regarding chronic toxicity endpoints
increased. By noting this, it becomes clear that without any
doubt ZEBET’s main tasks and focus currently lie and will
remain to lie in the replacement and reduction of animal
testing. In particular with regard to chronic toxicity end-
points, such research efforts are still ill funded and scat-
tered throughout Germany and to increase exchange and
collaboration a National Reference Center for Alternatives
to Animal Testing should be established which could be
hosted at ZEBET@BfR.
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